Skip to main content
SpringerLink
Log in

Pharmacologic Interventions in Acute Myocardial Infarction

  • Chapter
Topics in Clinical Pharmacology and Therapeutics

  • 189 Accesses

Abstract

Acute myocardial infarction (MI) is perhaps the most serious health problem in Western society, affecting about 1.3 million people per year in the United States (1). Despite substantial advances in therapy, mortality and morbidity remain high. Even after hospital admission, mortality averages 10–15%.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alpert JS, Braunwald E: Pathological and clinical manifestations of acute myocardial infarction. In Braunwald E (ed): Heart disease. A textbook of cardiovascular medicine, 2nd ed. WB Saunders, Philadelphia, p 1262, 1984.

    Google Scholar 

  2. Harper RW, Gold HK, Leinbach RC: Acute myocardial infarction. In Johnson RA, Haber E, Austen WB (eds): The practice of cardiology. Little, Brown, Boston, p 310, 1980.

    Google Scholar 

  3. Jaffe AS: Coronary heart disease. In Campbell JW, Frisse M (eds): Manual of medical therapeutics, 24th ed. Little, Brown, Boston, p 61, 1983.

    Google Scholar 

  4. Sobel BE, Braunwald E: The management of acute myocardial infarction. In Braunwald E (ed): Heart disease. A textbook of cardiovascular medicine, 2nd ed. WB Saunders, Philadelphia, p 1303, 1984.

    Google Scholar 

  5. Anderson JL, Marshall HW, Bray BE, et al.: A randomized trial of intracoronary streptokinase in the treatment of acute myocardial infarction. N Engl J Med 308: 1312, 1983.

    PubMed  CAS  Google Scholar 

  6. Lown B, Fakhrd AM, Hood WB, Thorn GW: The coronary care unit. JAMA 199: 188, 1967.

    PubMed  CAS  Google Scholar 

  7. Anderson JL: Current understanding of lidocaine as an antiarrhythmic agent: a review. Clin Ther 6: 125, 1984.

    PubMed  CAS  Google Scholar 

  8. Jewitt DE, Kishon Y, Thomas M: Lignocaine in the management of arrhythmias after acute myocardial infarction. Lancet 1: 266, 1968.

    Google Scholar 

  9. Rahimtoola SH, Sinno MZ, Loeb HS, et al.: Lidocaine infusion in acute myocardial infarction. Effects on left ventricular function. Arch Intern Med 128: 416, 1971.

    PubMed  CAS  Google Scholar 

  10. El-Sherif N, Scherlag BJ, Lazzara R, Hope RR: Reentrant ventricular arrhythmias in the late myocardial infarction period. IV. Mechanism of action of lidocaine. Circulation 56: 395, 1977.

    PubMed  CAS  Google Scholar 

  11. Anderson JL, Harrison DC, Meffin PJ, Winkle RA: Antiarrhythmic drugs: clinical pharmacology and therapeutic uses. Drugs 15: 271, 1978.

    PubMed  CAS  Google Scholar 

  12. LeLorier J, Gaenon D, LaTour Y, et al.: Pharmacokinetics of lidocaine after prolonged intravenous infusions in uncomplicated myocardial infarction. Ann Intern Med 87: 700, 1977.

    PubMed  CAS  Google Scholar 

  13. Routledge PA, Stargel WW, Wagner GS, Shand DG: Increased alpha-1-acid glycoprotein and lidocaine disposition in myocardial infarction. Ann Intern Med 93: 701, 1980.

    PubMed  CAS  Google Scholar 

  14. Alderman EL, Kerber RE, Harrison DC: Evaluation of lidocaine resistance in man using intermittent large dose infusion techniques. Am J Cardiol 34: 342, 1974.

    PubMed  CAS  Google Scholar 

  15. Lie KI, Wellens HJ, Van Capelle FJ, Durrer D: Lidocaine in the prevention of primary ventricular fibrillation. N Engl J Med 291: 1324, 1974.

    PubMed  CAS  Google Scholar 

  16. Haynes RE, Chinn RL, Copass MK, Cobb LA: Comparison of bretylium tosylate and lidocaine in management of out-of-hospital ventricular fibrillation. A randomized clinical trial. Am J Cardiol 48: 353, 1981.

    PubMed  CAS  Google Scholar 

  17. Valentine PA, Frew JL, Mashford ML, Sloman JG. Lidocaine in the prevention of sudden death in pre-hospital phase of acute infarction. N Engl J Med 29: 1327, 1974.

    Google Scholar 

  18. Lie KI, Liem KL, Lourditz WJ, et al.: Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after 300 mg intramuscular injection. Am J Cardiol 42: 486, 1978.

    PubMed  CAS  Google Scholar 

  19. Harrison DC: Should lidocaine be administered routinely to all patients after acute myocardial infarction? Circulation 58: 581, 1978.

    PubMed  CAS  Google Scholar 

  20. Wyman MG, Hammersmith L: Comprehensive treatment plan for the prevention of primary ventricular fibrillation in acute myocardial infarction. Am J Cardiol 33: 661, 1974.

    PubMed  CAS  Google Scholar 

  21. Lie KL, Wellens HJJ, Downar E, Durrer D: Observations on patients with primary ventricular fibrillation complicating acute myocardial infarction. Circulation 52: 755, 1975.

    PubMed  CAS  Google Scholar 

  22. Carruth JE, Silverman ME: Ventricular fibrillation complicating acute myocardial infarction: reasons against the routine use of lidocaine. Am Heart J 104: 545, 1982.

    PubMed  CAS  Google Scholar 

  23. Anderson JL: Procainamide—conventional and sustained release: update on pharmacology and clinical use. Clin Ther 7: 618, 1985.

    PubMed  CAS  Google Scholar 

  24. Kayden HJ, Brodie BB, Steele JM: Procaineamide. A review. Circulation 15: 118, 1957.

    PubMed  CAS  Google Scholar 

  25. Koch-Weser J, Klein SW, Foo-Canto LL: Antiarrhythmic prophylaxis with procainamide in acute myocardial infarction. N Engl J Med 281: 1253, 1969.

    PubMed  CAS  Google Scholar 

  26. Karlsson E: Procainamide and phenytoin. Comparative study of their antiarrhythmic effects at apparent therapeutic plasma levels. Br Heart J 37: 731, 1975.

    PubMed  CAS  Google Scholar 

  27. Campbell RWF, Dolder MA, Prescott LF, Talbot RG, Murray A, Julian DG: Comparison of procainamide and mexiletine in prevention of ventricular arrhythmias after acute myocardial infarction. Lancet 1: 1257, 1975.

    PubMed  CAS  Google Scholar 

  28. Myerburg RJ, Kessler KM, Kiem I, Pefkaros KC, Conde CA, Cooper D, Castellanos A: The relationship between plasma levels of procainamide, suppression of premature ventricular contractions, and prevention of recurrent ventricular tachycardia. Circulation 64: 280, 1981.

    PubMed  CAS  Google Scholar 

  29. Giardina EV, Heissenbuttel RH, Bigger JT Jr: Intermittent intravenous procaine amide to treat ventricular arrhythmias. Ann Intern Med 78: 183, 1973.

    PubMed  CAS  Google Scholar 

  30. Lima JJ, Goldfarb AL, Conti DR, Golden LH, Bascomb BL, Benedetti GM, Jusko WJ. Safety and efficacy of procainamide infusions. Am J Cardiol 43: 98, 1979.

    PubMed  CAS  Google Scholar 

  31. Anderson JL. Bretylium: an update on pharmacokinetic studies and clinical uses. In Rapaport E (ed): Cardiology update, p. 241, 1983.

    Google Scholar 

  32. Anderson JL, Patterson E, Conlon M, Pasyk S, Pitt B, Lucchesi BR: Kinetics of antifibrillatory effects of bretylium: correlations with myocardial drug concentrations. Am J Cardiol 46: 583, 1980.

    PubMed  CAS  Google Scholar 

  33. Bacaner MB, Schrienemachers D: Bretylium tosylate for suppression of ventricular fibrillation after experimental myocardial infarction. Nature 220: 494, 1968.

    PubMed  CAS  Google Scholar 

  34. Nowak RM, Bodnar TJ, Dronen S, Gentzkow G, Tomlanowich MC: Bretylium tosylate as initial treatment for cardiopulmonary arrest: randomized comparison with placebo. Ann Emerg Med 10: 2, 1981.

    Google Scholar 

  35. Luomanmaki K, Heikkila J, Hartel G: Bretylium tosylate: adverse effects in acute myocardial infarction. Arch Intern Med 135: 515, 1975.

    Google Scholar 

  36. Torresani J: Bretylium tosylate in patients with acute myocardial infarction. Am J Cardiol 54: 20A, 1984.

    Google Scholar 

  37. Furberg CD: Effect of antiarrhythmic drugs on mortality after myocardial infarction. Am J Cardiol 52: 32C, 1983.

    Google Scholar 

  38. Anderson JL, Lutz JR, Sanders SW, Nappi JM: Efficacy of intravenous pirmenol hydrochloride for treatment of ventricular arrhythmias: a controlled comparison with lidocaine. J Cardiovasc Pharmacol 5: 213, 1983.

    PubMed  CAS  Google Scholar 

  39. Anderson JL, Anastasiou-Nana M, Lutz JR, Writer SL: Comparison of intravenous lorcainide with lidocaine for acute therapy of complex ventricular arrhythmias: results of a randomized study with crossover option. J Am Coll Cardiol 5: 333, 1985.

    PubMed  CAS  Google Scholar 

  40. Ruberman W, Weinblatt E, Goldberg JD, Frank CW, Shapiro S: Ventricular premature beats and mortality after myocardial infarction. N Engl J Med 297: 750, 1977.

    PubMed  CAS  Google Scholar 

  41. Moss AJ, Davis HT, DeCamilla J, Bayer IW: Ventricular ectopic beats and their relation to sudden and nonsudden cardiac death after myocardial infarction. Circulation 60: 998, 1978.

    Google Scholar 

  42. The Multicenter Postinfarction Research Group: Risk stratification and survival after myocardial infarction. N Engl J Med 309: 331, 1983.

    Google Scholar 

  43. Anderson JL, Stewart JR, Crevey BJ: A proposal for the clinical use of flecainide. Am J Cardiol 53: 112B, 1984.

    Google Scholar 

  44. Roden DM, Reele SB, Higgins SB, et al.: Total suppression of ventricular arrhythmias by encainide: pharmacokinetic and electrocardiographic effects. N Engl J Med 302: 877, 1980.

    PubMed  CAS  Google Scholar 

  45. Giardina EGC, Bigger J J Jr: Antiarrhythmic effect of imipramine hydrochloride in patients with ventricular premature complexes without psychological depression. Am J Cardiol 50: 172, 1982.

    PubMed  CAS  Google Scholar 

  46. Pratt CM, Yepsen SC, Taylor AA, Mason DT, Miller RR, Quinones MA, Lewis RA: Ethmozine suppression of single and repetitive ventricular premature depolarizations during therapy: documentation of efficacy and long-term safety. Am Heart J 106: 85, 1983.

    PubMed  CAS  Google Scholar 

  47. Singh BN, Zipes DP (eds): Amiodarone: basic concepts and clinical applications. Am Heart J 106(pt 2), 1983.

    Google Scholar 

  48. Fogoros RN, Anderson KP, Winkle RA, Swerdlow CD, Mason JW. Amiodarone: Clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias. Circulation 68: 88, 1983.

    PubMed  CAS  Google Scholar 

  49. Shand DG (ed): New perceptives on beta blockers in patients with acute myocardial infarction. Miami, MEDED Publ, 1983.

    Google Scholar 

  50. Furberg CD, Friedewald WT, Eberlein KA (eds): Proceedings of the workshop on implications of recent beta-blocker trials for post-myocardial infarction patients. (Circulation 67(pt 2, no 6), 1983.

    Google Scholar 

  51. Reimer KA, Rasmussen MM, Jennings RB: Reduction by propranolol of myocardial necrosis following temporary coronary artery occlusion in dogs. Circ Res 33: 353, 1973.

    PubMed  CAS  Google Scholar 

  52. Rasmussen MM, Reimer KA, Kloner RA, Jennings RB: Infarct size reduction by propranolol before and after coronary ligation in dogs. Circulation 56: 794, 1977.

    PubMed  CAS  Google Scholar 

  53. Miura M, Thomas R, Ganz W, Sokol T, Shell WE, Toshimitsu T, Kwan AC, Singh BN: The effect of delay in propranolol administration on reduction of myocardial infarct size after experimental coronary artery occlusion in dogs. Circulation 59: 1148, 1979.

    PubMed  CAS  Google Scholar 

  54. Rude RE, Muller JE, Braunwald E. Efforts to limit the size or myocardial infarcts. Ann Intern Med 95: 736, 1981.

    PubMed  CAS  Google Scholar 

  55. Anderson JL, Rodier HE, Green LS: Comparative effects of beta-adrenergic blocking drugs on experimental ventricular fibrillation threshold. Am J Cardiol 51: 1196, 1983.

    PubMed  CAS  Google Scholar 

  56. Anastasiou-Nana M, Nanas J, Menlove RL, Anderson JL: Experimental antifibrillatory effects of calcium channel blockade with diltiazem: comparison with beta-blockade and nitroglycerin. J Cardiovasc Pharmacol 6: 780, 1984.

    PubMed  CAS  Google Scholar 

  57. Gang EL, Bigger JT Jr, Uhl EW: Effects of timolol and propranolol on inducible sustained ventricular tachyarrhythmias in dogs with subacute myocardial infarction. Am J Cardiol 53: 275, 1984.

    PubMed  CAS  Google Scholar 

  58. Patterson E, Holland K, Eller BT, Lucchesi BR: Ventricular fibrillation resulting from ischemia at a site remote from previous myocardial infarction. A conscious canine model of sudden coronary death. Am J Cardiol 50: 1414, 1982.

    PubMed  CAS  Google Scholar 

  59. Holland K, Patterson E, Lucchesi BR. Prevention of ventricular fibrillation by bretylium in a conscious canine model of sudden coronary death. Am Heart J 105: 711, 1983.

    PubMed  CAS  Google Scholar 

  60. Patterson E, Lucchesi BR: Antifibrillatory actions of d,l nadolol in a conscious canine model of sudden coronary death. J Cardiovasc Pharmacol 5: 737, 1983.

    PubMed  CAS  Google Scholar 

  61. Norwegian Multicenter Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304: 801, 1981.

    Google Scholar 

  62. Beta Blocker Heart Attack Study Group: The beta-blocker heart attack trial. JAMA 246: 2073, 1981.

    Google Scholar 

  63. Hjalmarson A, Elmfeldt D, Herlitz J, et al.: Effect on mortality of metoprolol in acute myocardial infarction. Lancet 11: 823, 1981.

    Google Scholar 

  64. Wilhelmsson C, Vedin JA, Wilhelmsen L, Tibbin G, Werko L: Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Preliminary results. Lancet 2: 1157, 1974.

    PubMed  CAS  Google Scholar 

  65. Multicentre International Study: Reduction in mortality after myocardial infarction by long-term beta-adrenoreceptor blockade using practolol. Br Med J 3: 735, 1975.

    Google Scholar 

  66. May GS: A review of long-term beta-blocker trials in survivors of myocardial infarction. Circulation 67 (pt 2, no 6): I–46, 1983.

    Google Scholar 

  67. Pedersen TR: The Norwegian multicenter study of timolol after myocardial infarction. Circulation 67 (pt 2, no 6): I–49, 1983.

    Google Scholar 

  68. Rodda BI: The timolol myocardial infarction study: an evaluation of selected variables. Circulation 67 (pt 2, no 6): I–101, 1983.

    Google Scholar 

  69. Goldstein S: Propranolol therapy in patients with acute myocardial infarction: the beta-blocker heart attack trial. Circulation 67 (pt 2, no 6): I–53, 1983.

    Google Scholar 

  70. Lichstein E, Morganroth J, Harrist R, Hubble E: Effect of propranolol on ventricular arrhythmia. The beta-blocker heart attack trial experience. Circulation 67 (pt 2, no 6): I–5, 1983.

    Google Scholar 

  71. Furberg CD, Byington RP: What do the subgroup analyses reveal about differential exposure to beta-blocker therapy? The beta-blocker heart attack trial experience. Circulation 67 (pt 2, no 6): I–98, 1983.

    Google Scholar 

  72. Baber NS, Wainwright-Evans D, Howitt G, et al.: Multicentre postinfarction trial of propranolol in 49 hospitals in the United Kingdom, Italy, and Yugoslavia. Br Heart J 44: 96, 1980.

    PubMed  CAS  Google Scholar 

  73. Hansteen V, Moinichen E, Lorentsen E, et al.: One year’s treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. Br Med J 284: 155, 1982.

    CAS  Google Scholar 

  74. Hjalmarson A, Herlitz J, Holmberg L, et al.: The Goteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation 67 (pt 2, no 6): I–26, 1983.

    Google Scholar 

  75. Cutler J A: A review of ongoing trials of beta blockers in the secondary prevention of coronary heart disease. Circulation 67 (pt 2, no 6): I–62, 1983.

    Google Scholar 

  76. Harrison DC: Beneficial effects of beta-blockers: a class action or individual pharmacologic spectrum? Circulation 67 (pt 2, no 6): I–77, 1983.

    Google Scholar 

  77. Taylor SH, Silke B, Ebbutt A, Sutton GC, Prout BJ, Burley DM: A long-term prevention study with oxprenolol in coronary heart disease. N Engl J Med 307: 1293, 1982.

    PubMed  CAS  Google Scholar 

  78. Baber NS, Lewis JA: Beta-adrenergic blockade and myocardial infarction: when should treatment start and for how long should it continue? Circulation 67 (pt 2, no 6): I–71, 1983.

    Google Scholar 

  79. Furberg CD: Additional data from the beta blocker heart trial. In Shand DG (ed): New perspectives on beta blockers in patients with acute myocardial infarction. Miami, MEDED Publ 1983: 19.

    Google Scholar 

  80. Friedewald WT: Beta-adrenergic blockade after myocardial infarction: clinical and public health implications of the reported beta-blocker clinical trials. Circulation 67 (pt 2, no 6): I–110, 1983.

    Google Scholar 

  81. May GS: A review of acute-phase beta-blocker trials in patients with myocardial infarction. Circulation 67 (pt 2, no 6): I–21, 1983.

    Google Scholar 

  82. Hjalmarson A, Herlitz J, Vedin A, et al.: The Swedish metoprolol trial: additional follow-up information. In Shand DG (ed): New perspectives on beta blockers in patients with acute myocardial infarction. Miami, MEDED Publ 1983: 9.

    Google Scholar 

  83. Hjalmarson A, ed. The Goteborg metoprolol trial in acute myocardial infarction. Am J Cardiol 53(13), 1984.

    Google Scholar 

  84. Ryden L, Ariniego R, Amman K, et al.: A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. N Engl J Med 308: 614, 1983.

    PubMed  CAS  Google Scholar 

  85. Hjalmarson A, Herlitz J. Limitation of infarct size by beta blockers and its potential role for prognosis. Circulation 67 (pt 2, no 6): I–68, 1983.

    Google Scholar 

  86. Yusuf S, Ramsdale D, Peto R, Furse L, Bennett D, Bray C, Sleight P: Early intravenous atenolol treatment in suspected acute myocardial infarction. Lancet 2: 273, 1980.

    PubMed  CAS  Google Scholar 

  87. The International Collaborative Study Group: Reduction of infarct size with the early use of timolol in acute myocardial infarction. N Engl J Med 310: 9, 1983.

    Google Scholar 

  88. Roberts R, Croft C, Gold HK, et al.: Effect of propranolol on myocardial-infarct size in a randomized blinded multicenter trial. N Engl J Med 311: 218, 1984.

    PubMed  CAS  Google Scholar 

  89. Gold HK, Leinbach RC, Harper RW: Usefulness of intravenous propranolol in predicting left anterior descending blood flow during anterior myocardial infarction. Am J Cardiol 54: 264, 1984.

    PubMed  CAS  Google Scholar 

  90. Byrd RC, Sung RJ, Marks J, Parmley WW: Safety and efficacy of esmolol (ASL-8052: an ultrashort-acting beta-adrenergic blocking agent) for control of ventricular rate in supraventricular tachycardias. J Am Coll Cardiol 3: 394, 1984.

    PubMed  CAS  Google Scholar 

  91. Oliva PB, Breckinridge JC: Arteriographic evidence of coronary arterial spasm in acute myocardial infarction. Circulation 56: 366, 1977.

    PubMed  CAS  Google Scholar 

  92. Come PC, Flaherty JT, Baird MG, Rouleau JR, Weisfeldt ML, Greene HL, Becker L, Pitt B: Reversal by phenylephrine of the beneficial effects of intravenous nitroglycerin in patients with acute myocardial infarction. N Engl J Med 293: 1003, 1975.

    PubMed  CAS  Google Scholar 

  93. Borer JS, Redwood DR, Levitt B, Cagin N, Bianchi C, Vallin H, Epstein SE: Reduction in myocardial ischemia with nitroglycerin or nitroglycerin plus phenylephrine administered during acute myocardial infarction. N Engl J Med 293: 1008, 1975.

    PubMed  CAS  Google Scholar 

  94. Gold HK, Leinbach RC, Sanders CA: Use of sub-lingual nitroglycerin in congestive heart failure following acute myocardial infarction. Circulation 46: 839, 1972.

    PubMed  CAS  Google Scholar 

  95. Flaherty JT, Reid PR, Kelly DT, Taylor DR, Weisfeldt ML, Pitt B: Intravenous nitroglyerin in acute myocardial infarction. Circulation 51: 132, 1975.

    PubMed  CAS  Google Scholar 

  96. Flaherty JT, Come PC, Baird MG, et al.: Effects of intravenous nitroglycerin on left ventricular function and ST segment changes in acute myocardial infarction. Br Heart J 38: 612, 1976.

    PubMed  CAS  Google Scholar 

  97. Bussmann WD, Passek D, Seidel W, Kaltenbach M: Reduction of CK and CK-MB indexes of infarct size intravenous nitroglycerin. Circulation 63: 615, 1981.

    PubMed  CAS  Google Scholar 

  98. Jaffe AS, Geltman EM, Tiefenbrunn A J, Ambos HD, Strauss HD, Sobel BE, Roberts R: Reduction of infarct size in patients with inferior infarction with intravenous glyceryl trinitrate. Br Heart J 49: 452, 1983.

    PubMed  CAS  Google Scholar 

  99. Ross JR Jr: Effects of afterload or impedance on the heart: afterload reduction in the treatment of cardiac failure. Cardiovasc Med 1115, 1977.

    Google Scholar 

  100. Franciosa JA, Giuha NH, Limas CJ, Rodriguera E, Cohn JN: Improved left ventricular function during nitroprusside infusion in acute myocardial infarction. Lancet 1: 650, 1972.

    PubMed  CAS  Google Scholar 

  101. Chatterjee K, Parmley WW, Ganz W, Forrester J, Walinsky P, Crexells C, Swan HJC: Hemodynamic and metabolic responses to vasodilator therapy in acute myocardial infarction. Circulation 48: 1183, 1973.

    PubMed  CAS  Google Scholar 

  102. Chatterjee K, Swan HGC: Vasodilator therapy in acute myocardial infarction. Mod Concepts Cardiovasc Dis 43: 119–26, 1974.

    PubMed  CAS  Google Scholar 

  103. Chatterjee K, Swan HJC, Kaushik VS, Jobin G, Magnusson P, Forrester JS: Effects of vasodilator therapy for severe pump failure in acute myocar dial infarction on short-term and late prognosis. Circulation 53: 797, 1976.

    PubMed  CAS  Google Scholar 

  104. Hockings BEF, Cope GD, Clarke GM, Taylor RR: Randomized controlled trial of vasodilator therapy after myocardial infarction. Am J Cardiol 48: 345, 1981.

    PubMed  CAS  Google Scholar 

  105. Chiariello M, Gold HK, Leinbach RC, Davis MA, Maroko PR: Comparison between the effects of nitroprusside and nitroglycerin on ischemic injury during acute myocardial infarction. Circulation 54: 766, 1976.

    PubMed  CAS  Google Scholar 

  106. Capurro NL, Kent KM, Epstein SE: Comparison of nitroglycerin-, nitroprusside-, and phentolamine-induced changes in coronary collateral function in dogs. J Clin Invest 39: 1067, 1977.

    Google Scholar 

  107. Mann T, Cohn PF, Holman L, Green LH, Markis JE, Philips DA: Effect of nitroprusside on regional myocardial blood flow in coronary artery disease. Circulation 57: 732, 1978.

    PubMed  CAS  Google Scholar 

  108. Durrer JD, Lie KI, VanCapelle FJL, Durrer D: Effect of sodium nitroprusside on mortality in acute myocardial infarction. N Engl J Med 306: 1121, 1982.

    PubMed  CAS  Google Scholar 

  109. Cohn JN, Franciosa JA, Francis GS: Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure. N Engl J Med 306: 1129, 1982.

    PubMed  CAS  Google Scholar 

  110. Ellrodt G, Chew CYC, Singh BN: Therapeutic implications of slow-channel blockade in cardiocirculatory disorders. Circulation 62: 669, 1980.

    PubMed  CAS  Google Scholar 

  111. Stone P, Antman E, Muller J, Braunwald E: Calcium channel blocking agents in the treatment of cardiovascular disorders. Part 2. Ann Intern Med 93: 886, 1980.

    PubMed  CAS  Google Scholar 

  112. Yellon DM, Hearse DJ, Maxwell MP, Chambers DE, Downey JM: Sustained limitation of myocardial necrosis 24 hours after coronary artery occlusion: verapamil infusion in dogs with small myocardial infarcts. Am J Cardiol 51: 1409, 1983.

    PubMed  CAS  Google Scholar 

  113. Forman R, Eng C, Kirk ES: Comparative effect of verapamil and nitroglycerin on collateral blood flow. Circulation 67: 1200, 1983.

    PubMed  CAS  Google Scholar 

  114. Urquhart J, Patterson RE, Bacharach SL, Green MV, Speir EH, Aamodt R, Epstein SE: Comparative effects of verapamil, diltiazem, and nifedipine on hemodynamics and left ventricular function during acute myocardial ischemia in dogs. Circulation 69: 382, 1984.

    PubMed  CAS  Google Scholar 

  115. Bache RJ, Dai X-Z, Schwartz JS: Effect of nifedipine on myocardial blood flow during exercise in dogs with chronic coronary artery occlusion. J Am Coll Cardiol 3: 143, 1984.

    PubMed  CAS  Google Scholar 

  116. Melin J A, Becker LC, Hutchins GM: Protective effect of early and late treatment with nifedipine during myocardial infarction in the conscious dog. Circulation 69: 131, 1984.

    PubMed  CAS  Google Scholar 

  117. Rahamthulla PM, Ashraf M, Schwartz A, Benedict J: Effects of diltiazem on anoxic injury in the isolated rat heart. J Am Coll Cardiol 1: 1081, 1983.

    Google Scholar 

  118. Bertrand ME, LaBlanche JM, Tilmant PY: Frequency of provoked coronary arterial spasm in 1089 consecutive patients undergoing coronary arteriography. Circulation 65: 1299, 1982.

    PubMed  CAS  Google Scholar 

  119. Anderson JL, Wagner JM, Datz FI, Christian PI, Bray BE, Taylor AT: Comparative effects of diltiazem, propranolol, and placebo on exercise performance using radionuclide ventriculography in patients with symptomatic coronary artery disease: results of a double-blind, randomized crossover study. Am Heart J 107: 698, 1984.

    PubMed  CAS  Google Scholar 

  120. Gerstenblith G, Ouyang P, Achuff SC, et al.: Nifedipine in unstable angina. A double-blind, randomized trial. N Engl J Med 306: 885–889, 1982.

    PubMed  CAS  Google Scholar 

  121. Parodi O, Simonetti I, L’Abbate A, Maseri A: Verapamil versus propranolol for angina at rest. Am J Cardiol 50: 923–928, 1982.

    PubMed  CAS  Google Scholar 

  122. Stone PH, Turi ZG, Muller JE: Efficacy of nifedipine therapy for refractory angina pectoris. Am Heart J 104: 672–681, 1982.

    PubMed  CAS  Google Scholar 

  123. Muller JE, Morrison J, Stone PH, et al.: Nifidipine therapy for patients with threatened and acute myocardial infarction: a randomized, double-blind, placebo-controlled comparison. Circulation 69: 740, 1984.

    PubMed  CAS  Google Scholar 

  124. Thuesen L, Jorgensen JR, Kvistgaard HJ, Vaeth M, Jensen EB, Jensen JJ, Hagerup L: Effect of verapamil on enzyme release after early intravenous administration in acute myocardial infarction: double-blind randomized study. Br Med J 286: 1107, 1983.

    CAS  Google Scholar 

  125. Sonnenblick EH, Frishman WH, LeJemtel TH: Dobutamine: a new synthetic cardioactive sympathetic amine. In Koch-Weser J (ed): Drug therapy. N Engl J Med 300:17, 1979.

    Google Scholar 

  126. Leier CV, Heban PT, Huss P, Bush CA, Lewis RP: Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation 58: 466, 1978.

    PubMed  CAS  Google Scholar 

  127. Maekawa K, Liang C-S, Hood WB: Comparison of dobutamine and dopamine in acute myocardial infarction. Effects of systemic hemodynamics, plasma catecholamines, blood flows, and infarct size. Circulation 67: 750, 1983.

    PubMed  CAS  Google Scholar 

  128. Gillespie TA, Ambos HC, Sobel BE, Roberts R: Effects of dobutamine in patients with acute myocardial infarction. Am J Cardiol 39: 5884, 1977.

    Google Scholar 

  129. Meyer SL, Curry GC, Donsky MS, Twieg DB, Parkey RW, Willerson JT: Influence of dobutamine on hemodynamics and coronary blood flow in patients with and without coronary artery disease. Am J Cardiol 38: 103, 1976.

    PubMed  CAS  Google Scholar 

  130. Francis GS, Sharma B, Hodges M: Comparative hemodynamic effects of dopamine and dobutamine in patients with acute cardiogenic circulatory collapse. Am Heart J 103: 995, 1982.

    PubMed  CAS  Google Scholar 

  131. Awan NA, Evenson MK, Needham KE, Beattie JM, Mason DT: Effect of combined nitroglycerin and dobutamine infusion in left ventricular dysfunction. Am Heart J 106: 35, 1983.

    PubMed  CAS  Google Scholar 

  132. Sherry S: Personal reflections on the development of thrombolytic therapy and its application to acute coronary thrombosis. Am Heart J 102: 1134, 1981.

    PubMed  CAS  Google Scholar 

  133. Roberts WC, Buja LM: The frequency and significance of coronary arterial thrombi and other observations in fatal acute myocardial infarction: a study of 107 necropsy patients. Am J Med 52: 425, 1972.

    PubMed  CAS  Google Scholar 

  134. DeWood MA, Spores J, Notske R, et al.: Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303: 897, 1980.

    PubMed  CAS  Google Scholar 

  135. Sharma GVRK, Cella G, Parisi AF, Sasahara AA: Thrombolytic therapy. N Engl J Med 306: 1268, 1982.

    PubMed  CAS  Google Scholar 

  136. European Cooperative Study Group for Streptokinase Treatment in Acute Myocardial Infarction: Streptokinase in acute myocardial infarction. N Engl J Med 301: 797, 1979.

    Google Scholar 

  137. Rentrop P, Blanke H, Karsch KR, Kaiser H, Kostering H, Leitz K: Selective intracoronary thrombolysis in acute myocardial infarction and unstable angina pectoris. Circulation 63: 307, 1981.

    PubMed  CAS  Google Scholar 

  138. Ganz W, Buchbinder N, Marcus H, et al.: Intracoronary thrombolysis in evolving myocardial infarction. Am Heart J 101: 4, 1981.

    PubMed  CAS  Google Scholar 

  139. Mathey DB, Kuck K-H, Tilsner V, Krebber H, Bleifeld W: Nonsurgical coronary artery recanalization in acute transmural myocardial infarction. Circulation 63: 489, 1981.

    PubMed  CAS  Google Scholar 

  140. Reduto LA, Smalling RW, Freund GC, Gould KL: Intracoronary infusion of streptokinase in patients with acute myocardial infarction: effects of reperfusion on left ventricular performance. Am J Cardiol 48: 403, 1981.

    PubMed  CAS  Google Scholar 

  141. Sheehan FH, Mathey DB, Schofer J, Krebber HJ, Dodge HT: Effect of interventions in salvaging left ventricular function in acute myocardial infarction: a study of intracoronary streptokinase. Am J Cardiol 52: 431, 1983.

    PubMed  CAS  Google Scholar 

  142. Smalling RW, Fuentes F, Matthews MW, et al.: Sustained improvement in left ventricular function and mortality by intracoronary streptokinase administration during evolving myocardial infarction. Circulation 68: 131, 1983.

    PubMed  CAS  Google Scholar 

  143. DeFeyter PJ, Eenige MJ, van der Wall EE, et al.: Effects of spontaneous and streptokinase-induced recanalization on left ventricular function after myocardial infarction. Circulation 67: 1039, 1983.

    CAS  Google Scholar 

  144. Schwarz R, Faure A, Katus H, von Olshausen K, Hofman M, Schuler G, Manthey J, Kubler W: Intracoronary thrombolysis in acute myocardial infarction: an attempt to quantitate its effect by comparison of enzymatic estimate of myocardial necrosis with left ventricular ejection fraction. Am J Cardiol 51: 1573, 1983.

    PubMed  CAS  Google Scholar 

  145. Laffel GL, Braunwald E: Thrombolytic therapy. A new strategy for the treatment of acute myocardial infarction. N Engl J Med 311: 710, 770, 1984.

    PubMed  CAS  Google Scholar 

  146. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB: The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size versus duration of coronary occlusion in dogs. Circulation 56: 786, 1977.

    PubMed  CAS  Google Scholar 

  147. Muller JE, Stone PH, Markis JE, Braunwald E: Let’s not let the genie escape from the bottle—again. N Engl J Med 304: 1294, 1981.

    PubMed  CAS  Google Scholar 

  148. Anderson JL, Marshall HW, Bray BE, et al.: A randomized trial of intracoronary streptokinase in the treatment of acute myocardial infarction. N Engl J Med 308: 1312, 1983.

    PubMed  CAS  Google Scholar 

  149. Anderson JL, Mcllvaine PM, Marshall HW, Bray BE, Yanowitz FG, Lutz JR, Menlove RL, Hagan AD: Long-term follow-up after intracoronary streptokinase for myocardial infarction. A randomized, controlled study. Am Heart J 108: 1402, 1984.

    PubMed  CAS  Google Scholar 

  150. Khaja F, Walton JA, Brymer JF, et al.: Intracoronary fibrinolytic therapy in acute myocardial infarction. Report of a prospective randomized trial. N Engl J Med 308: 1305, 1983.

    PubMed  CAS  Google Scholar 

  151. Kennedy JW, Ritchie JL, Davis KB, Fritz JK: Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med 309: 1477, 1983.

    PubMed  CAS  Google Scholar 

  152. Rentrop P, Feit F, Schneider R, Blanke H, Stecy P: Mt. Sinai/New York University randomized reperfusion trial. J Am Coll Cardiol 3: 525, 1984.

    Google Scholar 

  153. Furberg CD: Clinical value of intracoronary strep-tokinase. Am J Cardiol 53: 626, 1984.

    PubMed  CAS  Google Scholar 

  154. Furberg CD: Clinical value of intracoronary strep-tokinase. Am J Cardiol 53: 626, 1984.

    PubMed  CAS  Google Scholar 

  155. Schroder R, Biamino G, Leitner E-Rv, Lindere T, Bruggemann T, Heitz J, Vohringer H-F, Wegscheider K: Intravenous short-term infusion of streptokinase in acute myocardial infarction. Circulation 67: 536, 1983.

    PubMed  CAS  Google Scholar 

  156. Neuhaus KL, Tebbe U, Sauer G, Kreuzer H, Kostering H: High dose intravenous streptokinase in acute myocardial infarction. Clin Cardiol 6: 426, 1983.

    PubMed  CAS  Google Scholar 

  157. Ganz W, Geft I, Shah PK, et al.: Intravenous streptokinase in evolving acute myocardial infarction. Am J Cardiol 53: 1209, 1984.

    PubMed  CAS  Google Scholar 

  158. Rogers WJ, Mantle JA, Hood WP, Baxley WA, Whitlow PL, Reeves RC, Soto B: Prospective randomized trial of intravenous and intracoronary streptokinase in acute myocardial infarction. Circulation 68: 1051, 1983.

    PubMed  CAS  Google Scholar 

  159. Spann JF, Sherry S, Carabello BA, et al.: Coronary thrombolysis by intravenous streptokinase in acute myocardial infarction. Am J Cardiol 53: 655, 1984.

    PubMed  CAS  Google Scholar 

  160. Anderson JL, Marshall HW, Askins JC, Lutz JR, Sorensen SG, Menlove RL, Yanowitz FG, Hagan AD: A randomized trial of intravenous and intracoronary streptokinase in patients with acute myocardial infarction. Circulation 70: 606, 1984.

    PubMed  CAS  Google Scholar 

  161. Rogers WJ, Hood WP, Reeves RC, Whitlow PL: Randomized trial of intracoronary versus intravenous streptokinase in acute myocardial infarction [Abstract]. J Am Coll Cardiol 3: 525, 1984.

    Google Scholar 

  162. Taylor GJ, Mikell FL, Moses HW: Intravenous versus intracoronary streptokinase therapy for acute myocardial infarction in community hospitals. Am J Cardiol 54: 256, 1984.

    PubMed  CAS  Google Scholar 

  163. Schroder R: Systemic versus intracoronary streptokinase infusion in the treatment of acute myocardial infarction. J Am Coll Cardiol 1: 1254, 1983.

    PubMed  CAS  Google Scholar 

  164. Hartzler GO, Rutherford BD, McConahay DR, Johnson WL, McCallister BD, Gura GM, Conn RC, Crockett JE: Percutaneous transluminal coronary angioplasty with and without thrombolytic therapy for treatment of acute myocardial infarction. Am Heart J 106: 965, 1983.

    PubMed  CAS  Google Scholar 

  165. Schwarz F, Hofmann M, Schuler G, von Olshausen K, Zimmermann R, Kubler W: Thrombolysis in acute myocardial infarction: effect of intravenous followed by intracoronary streptokinase application on estimates of infarct size. Am J Cardiol 53: 1505, 1984.

    PubMed  CAS  Google Scholar 

  166. Hammerman H, Kloner RA, Briggs LL, Braunwald E: Enhancement of salvage of reperfused myocardium by early beta-adrenergic blockade (timolol). J Am Coll Cardiol 3: 1438, 1984.

    PubMed  CAS  Google Scholar 

  167. Telford AM, Wilson C: Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1: 1225, 1981.

    PubMed  CAS  Google Scholar 

  168. Furberg CD, May GS: Effect of long-term prophylactic treatment on survival after myocardial infarction. Am J Med 76: 76, 1984.

    PubMed  CAS  Google Scholar 

  169. TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial: Phase I findings. N Engl J Med 312: 932, 1985.

    Google Scholar 

  170. Elwood PC, Sweetnam PM: Aspirin and secondary mortality after myocardial infarction. Lancet 2: 1313, 1979.

    PubMed  CAS  Google Scholar 

  171. Aspirin Myocardial Infarction Study Research Group: A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 243: 661, 1980.

    Google Scholar 

  172. Temple R, Pledger GW: The FDA’s critique of the anturane reinfarction trial. N Engl J Med 302: 290, 1980.

    Google Scholar 

  173. Lewis HD, Davis JW, Archibald DG, et al.: Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veteran’s Administration Cooperative Study. N Engl J Med 309: 396, 1983.

    PubMed  Google Scholar 

  174. Persantine-Aspirin Reinfarction Study Research Group: Persantine and aspirin in coronary heart disease. Circulation 62: 449, 1980.

    Google Scholar 

  175. Klint CR, Stamler J: Secondary coronary prevention with Persantine and aspirin. J Am Coll Cardiol 5: 505, 1985.

    Google Scholar 

  176. Jolly SR, Lucchesi BR: Effect of BW755C in an occlusion-reperfusion model of ischemic myocardial injury. Am Heart J 106: 8, 1983.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Jeffrey L. Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Clinical Pharmacology Section, University of Southern California, School of Medicine, Los Angeles, California, 90033, USA

    Robert F. Maronde (Professor of Medicine, Head) (Professor of Medicine, Head)

Rights and permissions

Reprints and permissions

Copyright information

© 1986 Springer-Verlag New York Inc.

About this chapter

Cite this chapter

Anderson, J.L. (1986). Pharmacologic Interventions in Acute Myocardial Infarction. In: Maronde, R.F. (eds) Topics in Clinical Pharmacology and Therapeutics. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-4864-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-4864-4_5

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-9336-1

  • Online ISBN: 978-1-4612-4864-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation